ABM Therapeutics closes USD20m Series A+ round led by China Growth Capital

On August 7, ABM Therapeutics, abiopharmaceutical innovator focused on the development of small molecule drugs that can break the blood-brain barrier, announced the completion of its Series A+ round, raising 20 million US dollars.

On August 7, ABM Therapeutics, abiopharmaceutical innovator focused on the development of small molecule drugs that can break the blood-brain barrier, announced the completion of its Series A+ round, raising 20 million US dollars.

The round was led by China Growth Capital, with participation from Sinopharm, Panlin Capital, Ming Bioventures, as well as existing investors Kaitai Capital and LongDAC.

Proceeds from this financing round will be used to accelerate the clinical research of ABM-1310 and the development of several existing preclinical programs, further enriching the R&D pipeline and creating sustainable value in the development of small molecules that can break the blood-brain barrier.

Founded in 2015, AMB Therapeutics is a clinical-stage platform for the development of innovative small molecule drugs.

The company’s founder, Dr. Chen Chen, has more than 20 years of experience in central nervous system drug discovery in the United States.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/08/09/abm-therapeutics-closes-usd20m-series-a-round-led-by-china-growth-capital/.

Leave a Reply

Your email address will not be published. Required fields are marked *